Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05541627 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

StatusActive, Not Recruiting
PhasePhase 1/2
Started2022-10-12
View on ClinicalTrials.gov ↗

Amendment history

2026-05-12
Study Status, Sponsor/Collaborators, Oversight v7
Lead sponsorBrainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio)→AskBio France, SAS, a subsidiary of AskBio Inc.
2025-09-12
Study Status, Oversight v6
Primary completion dateestimated 2025-12-31→confirmed 2024-04-04
Completion date2029-12-31→2028-04
2024-08-05
Study Status v5
Re-verified, no change to tracked fields
2023-07-06
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v4
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 18→confirmed 5
Study sitesdetails revised at 1 of 1 site
2023-03-15
Study Identification, Study Status, Study Description, Conditions, Arms and Interventions v3
InterventionsBV-101 Gene Therapy (Genetic)→AB-1001 Gene Therapy (Genetic)
Study description+1 characters
[...] eatment with one-time intracerebral bilateral injections of BVAB-1011001 within the striatum (caudate and putamen). This study consi [...]
Study title+1 characters
A Study to Evaluate BVAB-1011001 Striatal Administration in Adults With Early Manifest Huntington's Disease
Show 2 earlier versions
2022-10-17
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2022-10-15→confirmed 2022-10-12
Study sites0→1
2022-09-19
Study Identification, Study Status, Study Design, Outcome Measures, Contacts/Locations v1
Study sites1→0
Secondary endpointsdetails revised at 1 of 7 entries
Study title-18 characters
PhI/II Dose-FindingA Study to Evaluate BV-101 Striatal Administration in Adults With Early Manifest Huntington's Disease
2022-09-13
Original filing
A Phase I/II Dose-Finding Study to Evaluate Striatal Administration of AB-1001 (previously BV-101) in Adults with Early Manifest Huntington's Disease
Trial Details
NCT Number NCT05541627
Lead Sponsor AskBio France, SAS, a subsidiary of AskBio Inc.
Conditions Huntington Disease
Enrollment 5 participants
Start Date 2022-10-12
Primary Completion 2024-04-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-14